ALNY Q2 2021 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$221M+112.1% YoY

Gross Profit

$182M82.4% margin

Operating Income

-$146M-66.3% margin

Net Income

-$190M-85.9% margin

EPS (Diluted)

$-1.61

QoQ Revenue Growth

+24.2%

Cash Flow

Operating Cash Flow

-$122M

Free Cash Flow

-$133M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$2.7B

Stockholders' Equity

$853M

Cash & Equivalents

$746M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$221M	$104M	+112.1%
Gross Profit	$182M	$84M	+116.3%
Operating Income	-$146M	-$199M	+26.5%
Net Income	-$190M	-$179M	-5.8%

Revenue Segments

Product

$161M100%

Royalty

$347,0000%

Geographic Segments

Non-US Or Europe

$17M50%

Europe

$10M30%

UNITED STATES

$7M20%